Psoriatic Arthritis

Findings reveal a need for distinct strategies to prevent cardiovascular events in patients with rheumatoid arthritis and psoriatic arthritis.

At weeks 12 and 24, the proportion of patients reporting high disease activity reduced from 16.7% to 8.3%, respectively.

This systematic review found 26 DMARDs in clinical development for spondyloarthritis, including psoriatic arthritis, but their target diversity was low.

According to the PRESTO tool, the risk of developing psoriatic arthritis in patients with psoriasis within 1 year was linked to a family history of psoriasis, joint or back stiffness, male sex, younger age, pain severity, and the use of biologic medications.

Changes in BMI were positively correlated with changes in IL-23 and significant positive correlations were observed between BMI and DAS28-CRP, CRP, IL-13, IL-17, leptin, and TNF-α.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

In the updated analysis, the interleukin-23 p19-subunit inhibitor also showed better skin efficacy.

Women with psoriatic arthritis reported higher mean pain and worse mean patient global assessment when compared with men.

In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.

At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.

Adam Dore, DO, discusses the recent developments in treating psoriatic arthritis and his predictions for the advancement of care in the upcoming year.

Etanercept was effective at 6 months of follow-up and remained so at 12 months, with low rates of adverse events.

Serum levels of BD-2 at baseline were shown to be significantly linked with subsequent clinical response in patients with psoriatic arthritis.

Celastrol may regulate core target proteins to alleviate the inflammatory response.

Guselkumab was able to provide minimal disease activity improvements from baseline through week 48 in adult patients with psoriatic arthritis.

Patients with unrestful sleep had significantly reduced health-related quality of life and significantly more depressive symptoms.

While most patients were interested in an online wellness program for managing their psoriatic arthritis, barriers, such as cost and fatigue, hindered their initiation of lifestyle adaptations.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

A pair of studies presented at EULAR 2023 offer perspective on the potential for postpartum depression as well as symptoms of depression and anxiety during pregnancy among women with rheumatic disease.

Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.

An analysis of data from the phase 4 MOSAIC trail is providing clinicians with a greater understanding of the effects of apremilast in people with uncontrolled psoriatic arthritis.

An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.

New data from EULAR 2023 offers a comparison of the levels of vascular inflammation among patients with psoriatic arthritis relative to healthy controls.

Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.

Janssen's efforts are accompanied by extensive data generation in patients of color and the creation of a diverse workforce.